This distribution collaboration includes the Niti-S Through the Scope (TTS) esophageal Stent, the flagship product of the South Korean company’s Niti-S Self-Expandable line of metal gastrointestinal (GI) stents.

The Niti-S TTS Esophageal Stent is intended for use in certain types of esophageal strictures caused by malignant tumors. According to the American Institute for Cancer Research, nearly 17,000 new cases of esophageal cancer occur annually. The vast majority of these cases occur in men.

Taewoong Medical CEO Kyongmin Shin said: “We are very pleased and proud to enter into this collaboration with Cook Medical, a leading global medical device company.

“We believe Cook Medical’s philosophy and focus towards continuous innovation in product development is akin to Taewoong Medical’s own philosophy. And I am confident that our partnership will bring the optimal stent solutions to our U.S. doctors and patients.”

The preloaded Niti-S TTS Esophageal Stent is deployed through a 10.5 Fr delivery system, which is unique to the U.S. market. This allows the stent to be introduced and placed through a scope with a conical tip designed to navigate tight strictures and tortuous anatomies.

In addition to the Niti-S TTS Esophageal Stent, Cook will also be the U.S. distributor for the Niti-S Esophageal Stent—a standard esophageal stent—as well as the Niti-S Biliary Stent.

Cook Medical’s endoscopy specialty vice president and Cook Winston-Salem president Barry Slowey said: “We’re excited to now be offering these stents and to continue our focus in supporting physicians in their treatment of diseases of the GI tract by adding Taewoong’s stent technologies to our existing Evolution and Zilver stent offerings.

“In addition, we’re honored to collaborate with Taewoong because we share a commitment to provide solutions that deliver patient care through innovation.”

Since 1963 Cook Medical has worked closely with physicians to develop technologies that eliminate the need for open surgery. Today we are combining medical devices, biologic materials and cellular therapies to help the world’s healthcare systems deliver better outcomes more efficiently.

Source: Company Press Release